Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Xyrem Daytime Sleepiness Confirmatory Data Expected In 2002

Executive Summary

Results from Orphan Medical's Xyrem trial examining daytime sleepiness in patients with narcolepsy are expected in the third quarter of 2002.

You may also be interested in...



Xyrem Risk Management Requires Patient Evaluation Every Three Months

Orphan Medical's risk management program for its cataplexy drug Xyrem will require a patient evaluation by the prescribing physician every three months

Xyrem Risk Management Requires Patient Evaluation Every Three Months

Orphan Medical's risk management program for its cataplexy drug Xyrem will require a patient evaluation by the prescribing physician every three months

Orphan Medical Xyrem Is “Approvable” Pending FDA Trial Site Review

FDA will conduct a clinical trial site review before approving Orphan Medical's narcoleptic cataplexy agent Xyrem, the company said following receipt of an "approvable" letter April 9

Related Content

UsernamePublicRestriction

Register

PS038000

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel